Advancing Alzheimer’s Clinical Trial Endpoints: Imaging Biomarkers, COA Challenges, Movement Measures, and CV Risk Webinar Replay

This webinar explores the critical aspects of conducting clinical trials in Alzheimer’s disease (AD) with a focus on innovative methodologies and challenges encountered. We will review the pivotal role of imaging biomarkers in characterizing patient eligibility, ensuring safety and evaluating therapeutic efficacy in AD trials. Next, we will discuss the evolving landscape and challenges associated with collecting endpoints for clinical outcome assessments (COAs) in a changing patient population. From there we will discuss the potential of leveraging gait and balance measures for detection and diagnosis of cognitive impairment and dementia and their significance in early intervention. Finally, we review the complexities of running trials in populations at high risk for cardiovascular (CV) disease, emphasizing the importance of baseline testing regardless of the drug being investigated. This webinar will provide insights that can inform sponsors to enhance the design and execution of AD clinical trials.